Every drug approved in 2022: A year of fewer new products, but gene-therapy firsts and new blockbusters

The year’s crop of US drug approvals won’t rival past vintages for quantity. But of the 45 drugs cleared for use by the FDA in 2022, a third are shaping up to be blockbusters, with high expectations for Lilly’s new diabetes drug, Bristol Myers Squibb’s TYK2 inhibitor and Gilead’s...

Click to view original post